#USA #Probiotics #Sacramento #Bifidobacterium #Evivo

Evivo Probiotic EVC001: Promising Results from Global Research Trials

Infinant Health is making waves in the world of infant health with its groundbreaking Evivo® infant probiotic, specifically the Bifidobacterium longum subsp. infantis EVC001 strain. Recently, the company shared an updated overview of the extensive research behind this promising probiotic, which has now spanned over a decade and includes numerous ongoing international studies. The evidence points to EVC001's critical role in developing a healthier gut microbiome in infants and enhancing their immune systems.

The Importance of B. infantis in Infant Development

Bifidobacterium longum subsp. infantis holds a key position in fostering gut health during infancy. Research suggests that its presence could be linked to lower incidences of allergies and autoimmune conditions. Parents utilizing Evivo have reported significant enhancements in their infants' health, emphasizing rapid observable results. Studies have shown that:

- 72% of parents noted a decrease in diaper rash.
- 63% saw reductions in gas and fussiness among their babies.
- 52% experienced extended sleep periods for their infants.

Evivo functions effectively in tandem with Human Milk Oligosaccharides (HMOs) found in breast milk and select formulas, working to:

- Replenish beneficial bacteria in 100% of babies.
- Cultivate a healthier gut microbiome.
- Promote comfortable digestion.
- Support the developing immune systems of infants.

Rising Global Research Momentum

The science behind EVC001 is gaining traction, with fourteen research studies underway focused on its effects in infants. Among the most notable initiatives is the GPPAD SINT1A Trial, which is arguably one of the most comprehensive studies examining early-life immune health. Conducted in Europe and the UK, this randomized, placebo-controlled trial has enrolled 1,149 infants. It aims to determine if daily EVC001 supplementation during the initial year can mitigate the risk of developing type 1 diabetes-related autoimmune responses. It marks the largest investigation into how an infant probiotic might influence the risk of autoimmune diseases through microbiome health.

Additionally, the BACH Trial, a proof-of-concept study, involves 286 infants who received EVC001 during their first three months. This study will look into allergy development up to the age of two, with results anticipated next year. Previous findings indicate that EVC001 helps lower fecal pH, reduce intestinal inflammation markers, and increase beneficial microbial metabolites—factors that are thought to correlate with healthier immune maturation at an early age.

Scientific Foundation and Commitment to Rigor

EVC001 is increasingly being recognized as one of the most thoroughly researched infant probiotics available globally. Its credibility stems from:

- Numerous randomized controlled clinical trials.
- Peer-reviewed publications.
- Mechanistic studies focused on immune signaling and microbial metabolites.
- A robust two-decade foundation of academic research that originated at UC Davis.

To date, Evivo products have been enjoyed over five million times, positively impacting the health of more than 70,000 infants.

Infinant Health remains dedicated to grounding its practices in meticulous scientific investigation. As CEO Mike Johnson articulated, the current findings shed light on the importance of the formative months of life in determining long-term health, highlighting the necessity for continued scientific focus on Evivo's B. infantis strain.

About Infinant Health

Infinant Health, previously known as Evolve Biosystems, is committed to transforming the health trajectory of individuals through meticulous research into gut microbiome science. Their product pipeline is designed specifically to enhance infant well-being while garnering support from prominent investors, including the Bill Gates Foundation and Johnson & Johnson. For more information and to purchase Evivo products, visit Evivo's official website.